Professional Documents
Culture Documents
Dr. Sarma - Hellp Complication Peb
Dr. Sarma - Hellp Complication Peb
Nama : dr. SarmaLumbanraja, SpOG(K) Tpt/tgl. Lahir : Pakpahan, 30 Juli 1959 Agama : Kristen JenisKelamin : Perempuan Pendidikan : SpesialisObstetridanGinekologi FK USU (1998) Jabatan : StafObstetridanGinekologi FK USU Alamat : PabrikTenun 35A, Medan 20118 No. Telp : (061) 4523-085 No. HP : 08126536472
Sarma LUMBANRAJA Department of Obstetrics and Gynecology Faculty of Medicine, Universitas Sumatera Utara
Introduction
Pregnancy Induced Hypertension:
BP > 140/90 mmHg after 20 weeks of gestation
Preeclampsia:
+ Proteinuria> 300 mg/24 h
Introduction
HELLP Syndrome:
0.2-0.6 % in all pregnancy Severe preeclampsia 4-12 % HELLP Hemolysis Elevated liver enzymes Low platelet
Abnormal Plasentation Hypoxia Placenta-derived agents : ??? Microvascular endothelial damage Intravascular platelet activation and deposition Stimulates secretion of Thromboxane A2 & serotonin Vasoconstriction & more platelet deposition/agregation & damage to the blood vessel wall
Vasoconstriction & more platelet deposition/agregation & damage to the blood vessel wall
Hypertension Circulating (serum) platelets Actual platelet count Further vessel narrowing Hepatocellular hypoxia RBC damage
Hepatocellular& Microangiopathiche periportal molysis necrosis Liver enzyme Liver rupture LDH Hemoglobin
Hipertenson
Proteinuria
HELLP
Eclampsia
Normal Glomerulus
Glomerulusw/ Endotheliosis
Vascular Defect
Placental ischemia
DEVELOPMENT OF STAGE 1
Poor placentation
C. W. Redman et al., Science 308, 1592 -1594 (2005) Used with permission
National Institute of Health (NIH) National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, (2000)
Uterine spiral artery unwinds and becomes a wider, flaccid tube to accommodate increased blood flow.
Uterine spiral artery remains tightly coiled, diminishing placental blood flow
THE RESULT:
Poor placentation, or a decreased capacity of the uteroplacental circulation. This causes placental hypoxia, resulting in oxidative stress.
Pathophysiology is generally established before 20 weeks.
(NIH, 2000)
DEVELOPMENT OF STAGE 2
Evidence of Maternal Disease Process
Gilbert E.S., & Harmon J.S. (2003). Hypertensive Disorders. In Manual of High Risk Pregnancy and Delivery ( p. 451). St Louis, MO: Mosby.
Toxic factors released by the placenta are believed to cause maternal endothelial dysfunction by one or more of following mechanisms: 1. The factors are directly toxic to endothelial cells 2. The factors stimulate maternal oxidative stress 3. The factors stimulate/activate inflammatory cytokines
Roberts, J.M., Gammill H.S. (2005) Gilbert & Harmon (2003) p. 451
Stage 1
Stage 2
Maternal Disease
Fetal Effects
Increased production of free radicals and lipid peroxides +endothelial cell damage Inflammatory cytokines + endothelial damage
2002 Phase 2 study of the use of bevacisumab (VEGF neutralizing antibody) in colorectal cancer
Tumor progression is slower Better survival
BUT
HYPERTENSION (19/68) AND PROTEINURIA (17/68) WAS FOUND
Hypertension
VEGF interaction with VEGF-R on endothelial cells induces the production NO and PG
Proteinuria
VEGF is critically involved in the maintenance of GBM barrier Excision of one VEGF A allele in the podocyte of mice causes endotheliosis and proteinuria (Eremina, 2003)
Relevant protein
Soluble Small enough to cross placental barrier Able to target endothelium
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
Sharon E. Maynard, Jiang-Yong Min,JaimeMerchan,Kee-Hak Lim, Jianyi Li, SusantaMondal,Towia A. Libermann,James P. Morgan,Frank W. Sellke, Isaac E. Stillman, Franklin H. Epstein, Vikas P. Sukhatme, and S. AnanthKarumanchi J Clin Invest 2003; 111: 649-658
PROANGIOGENIC vs ANTIANGIOGENIC
PIGF VEGF
SfLT1
PROANGIOGENIC (Normal)
ANTIANGIOGENIC (PE)
In Preeclampsia, the soluble receptor sFlt catches many VEGF and PLGF molecules
HYPOTHESIS
Histopathological analysis of renal tissue from one representative Fc-treated pregnant rat (upper panel), one sFlt1treated pregnant rat (middle panel). H&E stain shows capillary occlusion in the sFlt1 treated animal with enlarged glomeruli and swollen endothelial cells compared to Fc control animal.
IN NORMAL PREGNANCY
Increased of sFlt-1 Strevens (2003): in kidney biopsy of normal pregnant women 1 month beforedelivery, glomerularendotheliosis is found in 5/12 patients.
Preeclampsia could be the occurrence of a PHYSIOLOGICAL process during which the maternal endothelium is impaired because of presence of circulating placental factor
TGF-
Signaling by TGF-b family members, which includes TGF-bs, activins and BMPs, occurs via specic cell surface type I and type II receptors that are endowed with serine/threoninekinase activity. Accessory receptors endoglin and betaglycan modulate TGF-b family signaling via type I and type II receptors. Soluble endoglin and betaglycan can sequester ligand and thereby inhibit receptor binding. In most cells TGF-b signals via TbRII and ALK5. In endothelial cells (depicted here) it signals also via another type I receptor ALK1. Activins signal via ActRII and ALK4. BMPs signal via BMPRII and ActRII and type I receptors ALK1, ALK2, ALK3 and ALK6. The type I receptors act downstream of type II receptor and determine the signaling specicity of the receptor complex. Activated type I receptors initiate intracellular signaling by phosphorylatingspecic R-Smads. Activation of ALK1, ALK23, ALK3 and ALK6 leads to phosphorylation of Smad1, Smad5 and Smad8, and Smad2 and Smad3 are phosphorylated by ALK4, ALK5 and ALK7. Activated R- Smads assemble with Smad4 in heteromeric complexes that accu- mulate in the nucleus. There these complexes regulate specic gene expression responses by binding to DNA together with other DNA binding transcription factors. Abbreviatons: ActR, activin receptor; BMP, bone morphogenetic protein; BMPR, BMP receptor; sEnd, soluble endoglin; transforming growth factor-b; TbR, TGF-brecep- tor; TF, transcription factor
TGF-
TGF-1 induces vasorelaxation through activation of eNOS TGF-1 stimulate production of PGI2
sFlt-1: preeclampsia Soluble endoglins: HT + modest Proteinuria sFlt-1 + sEng: PE + Liver disorder
Glomerular disorder
sFlt1-injected rats showed moderate to severe endotheliosis with complete occlusion of capillary lumens. sFlt1+sEng-treated rats showed extremely swollen glomeruli and marked endotheliosis with protein resorption droplets in the podocytes.
Liver disorder
Liver histology in the control, sEng, sFlt1 and sFlt1+sEng groups. Ischemic changes with multifocal necrosis were noted in the sFlt1+sEng group. Control group and rats given sEng or sFlt1 showed no changes.
Peripheral blood smear (Wright stain) of control, sEng, sFlt1 and sFlt1+sEng groups. A representative smear in the sFlt1+sEng group showed active schistocytes (arrowheads) and reticulocytosis (arrows). No hemolysis was seen in the other groups.
Recombinant VEGF-121 was shown to suppress the maternal syndrome of preeclampsia in rats. Tobacco smoke (?) was found to suppress the secretion of sFlt-1 by syncytiotrophoblasts The role of endoglin in HELLP syndrome has not been confirmed